<unk> , technically known as recombinant human papillomavirus vaccine types 6, 11, 16, 18, is a vaccine for use in the prevention of certain strains of human papillomavirus (HPV), developed by Merck & Co. High-risk human papilloma virus (hr-HPV) genital infection is the most common sexually transmitted infection among women. The HPV strains that<unk>  protects against are sexually transmitted, specifically HPV types 6, 11, 16 and 18. HPV types 16 and 18 cause an estimated 70% of cervical cancers, and are responsible for most HPV-induced anal, vulvar, vaginal, and penile cancer cases. HPV types 6 and 11 cause an estimated 90% of genital warts cases. HPV type 16 is responsible for almost 90% of HPV-positive oropharyngeal cancers, and the prevalence is higher in males than females. Though<unk>  does not treat existing infection, vaccination is still recommended for HPV-positive individuals, as it may protect against one or more different strains of the disease. The vaccine was approved for medical use in the United States in 2006, initially for use in females aged 9–26. In 2007, the Advisory Committee on Immunization Practices (ACIP) recommended<unk>  for routine vaccination of girls aged 11 and 12 years. As of August 2009, vaccination was recommended for both males and females before adolescence and the beginning of potential sexual activity. By 2011, the vaccine had been approved in 120 other countries. In 2014, the U.S. Food and Drug Administration (FDA) approved a nine-valent version,<unk>  9, to protect against infection with the strains covered by the first generation of<unk>  as well as five other HPV strains responsible for 20% of cervical cancers (types 31, 33, 45, 52, and 58). In 2018, the FDA approved expanded use of<unk>  9 for individuals aged 27 through 45 years old.
Gardasil
WebTeb
Veterinarian
Street medic
Limen
Sultiame
Plague doctor
SmiNet